A Call to Action to Address Sex Differences in Alzheimer Disease Clinical Trials-Reference-Cited by-同舟云学术

A Call to Action to Address Sex Differences in Alzheimer Disease Clinical Trials

Published:2023-08-01 Issue:8 Volume:80 Page:769
ISSN:2168-6149
Container-title:JAMA Neurology
language:en
Short-container-title:JAMA Neurol

Author:

Buckley Rachel F.¹²,Gong Jessica³⁴,Woodward Mark³⁴

Affiliation:

1. Department of Neurology, Massachusetts General Hospital/Harvard Medical School, Boston

2. Center for Alzheimer Research and Treatment, Brigham and Women’s Hospital, Boston, Massachusetts

3. George Institute for Global Health, University of New South Wales, Sydney, Australia

4. George Institute for Global Health, Imperial College London, London, UK

Abstract

This Viewpoint calls for comprehensive investigations into sex differences associated with treatments in existing Alzheimer disease and integration into future Alzheimer disease and related dementia clinical trials.

Publisher

American Medical Association (AMA)

Subject

Neurology (clinical)

Link

https://jamanetwork.com/journals/jamaneurology/articlepdf/2804753/jamaneurology_buckley_2023_vp_230007_1691786967.64316.pdf

Reference10 articles.

1. Lecanemab in early Alzheimer’s disease.;van Dyck;N Engl J Med

2. Two randomized phase 3 studies of aducanumab in early Alzheimer’s disease.;Budd Haeberlein;J Prev Alzheimers Dis,2022

3. Menopause status moderates sex differences in tau burden: a Framingham PET Study.;Buckley;Ann Neurol,2022

4. Sex differences in the association of global amyloid and regional tau deposition measured by positron emission tomography in clinically normal older adults.;Buckley;JAMA Neurol,2019

5. Sex-specific association of apolipoprotein E with cerebrospinal fluid levels of tau.;Hohman;JAMA Neurol,2018

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of the X Chromosome in Alzheimer Disease Genetics;JAMA Neurology;2024-09-09

2. Considering challenges for the new Alzheimer's drugs: Clinical, population, and health system perspectives;Alzheimer's & Dementia;2024-08-06

3. The higher benefit of lecanemab in males compared to females in CLARITY AD is probably due to a real sex effect;2024-07-12

4. Neglecting sex and gender in research is a public-health risk;Nature;2024-05-15

5. Low-Dose Radiation Therapy Impacts Microglial Inflammatory Response without Modulating Amyloid Load in Female TgF344-AD Rats;Journal of Alzheimer's Disease;2024-04-02